Publications
708
Citations
45,865
Est. group size
~24
Recurring co-author estimate
Active years
54
Publishing since 1973
Philip S. Low's research focuses on designing molecules that can selectively find and bind to disease-related cells, such as cancer cells or inflamed immune cells, using targets like folate receptors and prostate-specific membrane antigen. These targeting molecules are then linked to imaging agents, drugs, or radiotherapy to help detect and treat diseases including various cancers, atherosclerosis, and autoimmune heart inflammation (myocarditis). The lab also works on engineered immune cells (CAR T cells) and fluorescent dyes that help surgeons visually identify tumor tissue during surgery.
Publication output has been relatively steady over the past decade, with year-to-year fluctuation and a notable spike in 2023, but no clear long-term increase or decline.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Folate receptor β-targeted Positron emission tomography imaging of activated macrophages in experimental myocardial infarction
Journal of Nuclear Cardiology · 2026
- Abstract LB023: Design of a ligand targeted radiotherapy for treatment of bone metastasis
Cancer Research · 2026
- Single-cell to pre-clinical evaluation of <i>Trem2</i> , <i>Folr2</i> , and <i>Slc7a7</i> as macrophage-associated biomarkers for atherosclerosis
Cardiovascular Research · 2025
- Use of a universal targeting CAR T cell to simultaneously kill cancer cells and cancer-associated fibroblasts
Frontiers in Immunology · 2025
- Design of a Pan-Tumor Fluorescence Imaging Cocktail for Fluorescence-Guided Surgery
Bioconjugate Chemistry · 2025
- A fibroblast activation protein targeted optical tracer for identifying primary and metastatic sarcoma during resection
EJNMMI Research · 2025
- Abstract 590: Prostate specific membrane antigen targeted PRMT5 inhibition re-sensitizes cancer cells to radiation therapies
Cancer Research · 2025
- Abstract 1864: Folate-mediated delivery of tumor-suppressive miRNA-34a to treat osteosarcoma
Cancer Research · 2025
- Addendum: Assessment of cholecystokinin 2 receptor (CCK2R) in neoplastic tissue
Oncotarget · 2025
- Tumor-targeted fluorescent dyes for fluorescence-guided surgery: preclinical and clinical results
2025
- Abstract 6692: The combination of 5-methyltetrahydrofolate and nigericin enhances the cytosolic release of chemically modified miRNA-34a, significantly boosting its anti-tumoral activity
Cancer Research · 2025
- Abstract 5735: Design of a peptide-targeted radiotherapy for treatment of bone cancers
Cancer Research · 2025
- Abstract 1903 Assessing the Retention of a Hydroxyapatite-Binding Peptide in Live Tissues
Journal of Biological Chemistry · 2025
- Comparing Two Folate Receptor β-Targeted Tracers in a Rat Model of Experimental Autoimmune Myocarditis
ACS Pharmacology & Translational Science · 2025
- A mechanistic model for dynamics between CAR T cells and target cells captures features that determine killing profiles
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Cancer Research×25
- Bioconjugate Chemistry×11
- Oncotarget×9
- Frontiers in Immunology×7
- bioRxiv (Cold Spring Harbor Laboratory)×7
- Aikaterini Voulgaridou
Medicine · Indiana University
- PS Low
Medicine · Purdue University West Lafayette
- Patrick G. Gallagher
Medicine · The Ohio State University
- Haripriya Sakthivel
Medicine · Purdue University West Lafayette
- Angelo D’Alessandro
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile